Asia-Pacific Digital Therapeutic (DTx) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Asia-Pacific Digital Therapeutic (DTx) Market Size

• The Asia-Pacific digital therapeutic (DTx) market size was valued at USD 4.66 billion in 2024 and is expected to reach USD 25.08 billion by 2032, at a CAGR of 23.40% during the forecast period
• The market growth is primarily driven by the increasing prevalence of chronic diseases, rising healthcare digitalization, and the growing focus on cost-effective and patient-centric care delivery across the region
• In addition, expanding smartphone penetration, greater internet accessibility, and supportive regulatory frameworks are enhancing patient engagement and encouraging widespread adoption of DTx solutions. These dynamics are propelling the Asia-Pacific DTx market forward, solidifying its role in the region’s evolving digital health ecosystem

Asia-Pacific Digital Therapeutic (DTx) Market Analysis

• Digital therapeutics (DTx), which deliver evidence-based therapeutic interventions via software to prevent, manage, or treat medical conditions, are becoming an integral component of the healthcare landscape in the Asia-Pacific region due to their scalability, remote access capabilities, and ability to support chronic disease management and mental health care
• The growing demand for DTx in Asia-Pacific is primarily driven by the rising incidence of lifestyle-related chronic diseases, increasing focus on preventive healthcare, and heightened awareness of digital health solutions among both patients and healthcare providers
• Japan dominated the Asia-Pacific digital therapeutic (DTx) market with the largest revenue share of 37.3% in 2024, supported by its advanced healthcare infrastructure, aging population, and favorable regulatory pathways, with notable progress in the adoption of digital platforms for mental health and chronic disease management
• India is expected to be the fastest growing country in the Asia-Pacific digital therapeutic (DTx) market during the forecast period, owing to increasing smartphone penetration, improved internet connectivity, growing burden of chronic conditions, and rising focus on affordable digital healthcare solutions
• Group purchase organization segment dominated the Asia-Pacific digital therapeutic (DTx) market with a market share of 54.6% in 2024, driven by its ability to streamline procurement, reduce costs, and enable large-scale adoption through healthcare institutions and employer networks

Report Scope and Asia-Pacific Digital Therapeutic (DTx) Market Segmentation       

Asia-Pacific Digital Therapeutic (DTx) Market Trends

“Personalized and AI-Driven Therapeutic Platforms”

• A significant and accelerating trend in the Asia-Pacific DTx market is the integration of artificial intelligence (AI) and personalized care algorithms to deliver tailored digital therapies that adapt to patient behaviors, clinical needs, and engagement levels. This innovation is significantly enhancing treatment adherence and patient outcomes across chronic and mental health conditions
  • For instance, CureApp (Japan) offers AI-powered DTx for conditions such as nicotine addiction and hypertension, providing individualized feedback and therapeutic plans. Similarly, India-based JOGO Health utilizes AI-driven biofeedback for neurological disorders, enabling remote rehabilitation
• AI integration in DTx platforms allows continuous monitoring and real-time data analysis to dynamically adjust treatment protocols, issue predictive alerts, and enable proactive health interventions. This level of personalization fosters improved engagement and measurable clinical benefits
• In addition, integration with wearables and mobile apps facilitates seamless data flow and patient-provider connectivity. Multilingual and culturally adaptive interfaces are further boosting DTx adoption across diverse demographic segments in the region
• This trend toward intelligent, real-time, and patient-specific digital health interventions is rapidly transforming the region’s approach to chronic care, with companies innovating to meet rising demand for holistic and accessible digital therapies

Asia-Pacific Digital Therapeutic (DTx) Market Dynamics

Driver

“Rising Burden of Chronic Diseases and Digital Health Ecosystem Expansion”

• The growing prevalence of chronic conditions such as diabetes, hypertension, cardiovascular, and mental health disorders, alongside a rapidly expanding digital health ecosystem, is a key driver accelerating the adoption of digital therapeutics in Asia-Pacific
  • For instance, in August 2024, Wellthy Therapeutics partnered with a leading Indian healthcare network to launch a DTx platform for chronic disease management, extending care access to remote and underserved populations. Such partnerships are reinforcing the utility of DTx in scalable and affordable healthcare delivery
• The widespread use of smartphones, expanding internet connectivity, and supportive government initiatives such as Japan’s Society 5.0 vision and India’s Ayushman Bharat Digital Mission are further enabling infrastructure for DTx deployment.
• As healthcare providers increasingly integrate digital tools into patient care, DTx platforms are becoming vital in supporting long-term disease management, improving access, and reducing overall care costs

Restraint/Challenge

“Data Privacy Concerns and Regulatory Uncertainty”

• Privacy concerns and regulatory inconsistencies remain a significant challenge hindering the broader adoption of DTx solutions in Asia-Pacific, particularly in emerging markets where data protection laws are still evolving
  • For instance, varying levels of cybersecurity enforcement and data handling practices across countries raise concerns about unauthorized data access, especially for platforms collecting sensitive patient health information. These concerns can reduce user trust and hinder DTx adoption
• To address this, companies must ensure compliance with country-specific privacy laws such as Japan’s APPI and India’s DPDP Act, implement strong encryption, and maintain transparent data practices
• In addition, the absence of standardized DTx regulatory frameworks across many Asia-Pacific countries results in unclear pathways for clinical validation, product approval, and reimbursement. This regulatory uncertainty creates entry barriers for both local startups and global firms looking to scale
• Building a consistent, transparent, and patient-centric regulatory ecosystem—alongside public awareness campaigns and digital literacy initiatives—will be essential to overcoming these barriers and unlocking the full potential of DTx in the region

Asia-Pacific Digital Therapeutic (DTx) Market Scope

The market is segmented on the basis of product and service type, application, purchase mode, and sales channel.

• By Product and Service Type

On the basis of product and service type, the Asia-Pacific digital therapeutic (DTx) market is segmented into hardware products, solutions/software, and services. The solutions/software segment dominated the market with the largest revenue share of 61.3% in 2024, driven by its scalability, cost-efficiency, and ability to provide customized, interactive therapies across various chronic and behavioral health conditions. These software solutions are frequently integrated with smartphones, wearables, and cloud platforms, allowing for real-time patient engagement and progress tracking.

The hardware products segment is expected to witness the fastest growth rate of 19.4% from 2025 to 2032, fueled by the increasing integration of wearable biosensors and smart monitoring devices in therapeutic ecosystems. These tools enable continuous patient data collection and feedback, enhancing the precision and personalization of digital therapies across the region.

• By Application

On the basis of application, the Asia-Pacific digital therapeutic (DTx) market is segmented into treatment/care-related applications and preventive applications. The treatment/care-related applications segment dominated the market with a revenue share of 57.4% in 2024, primarily due to the growing demand for digital tools in managing chronic diseases such as diabetes, hypertension, and mental health disorders. These solutions help improve treatment adherence and support remote monitoring for better clinical outcomes.

The preventive applications segment is expected to grow at the fastest CAGR of 20.8% from 2025 to 2032, driven by rising awareness around preventive healthcare, increasing use of lifestyle modification programs, and the growing role of digital platforms in encouraging early intervention strategies for at-risk populations.

• By Unlocking Mechanism

On the basis of purchase mode, the Asia-Pacific digital therapeutic (DTx) market is segmented into group purchase organization (GPO) and individual. The group purchase organization segment dominated the market with the largest share of 54.6% in 2024, supported by healthcare institutions and employers procuring DTx solutions in bulk to reduce costs and expand access among patients and workforce populations. These models ensure wider implementation and reduce patient acquisition costs for DTx developers.

The individual segment is projected to grow at the fastest CAGR of 21.2% from 2025 to 2032, propelled by increasing consumer awareness, self-management of chronic diseases, and rising adoption of mobile-based health apps purchased directly via app stores or company websites.

• By Sales Channel

On the basis of sales channel, the Asia-Pacific digital therapeutic (DTx) market is segmented into B2B and B2C. The B2B segment led the market with a revenue share of 63.6% in 2024, owing to strategic collaborations between digital therapeutic providers and hospitals, payers, and corporations. These partnerships often include integration with existing care platforms and insurance models, enabling structured and large-scale deployment.

The B2C segment is anticipated to witness the fastest growth rate of 22.5% during 2025–2032, driven by increasing digital health literacy, rising internet and smartphone penetration, and the growing preference for self-guided digital health tools among younger, tech-savvy consumers across urban and semi-urban regions.

Asia-Pacific Digital Therapeutic (DTx) Market Regional Analysis

• Japan dominated the Asia-Pacific digital therapeutic (DTx) market with the largest revenue share of 37.3% in 2024, supported by its advanced healthcare infrastructure, aging population, and favorable regulatory pathways, with notable progress in the adoption of digital platforms for mental health and chronic disease management
• Consumers and healthcare providers in Japan highly value the clinical validation, personalization, and remote care features offered by DTx platforms, leading to widespread integration into the country’s healthcare system
• This strong market position is further supported by favorable regulatory frameworks, high digital literacy, and active collaborations between DTx developers and public health institutions, positioning Japan as a leader in driving digital transformation within the region’s therapeutic landscape

Asia-Pacific Digital Therapeutic (DTx) Market Insight

The Asia-Pacific digital therapeutic (DTx) market is projected to grow at the fastest CAGR of 23.2% during the forecast period of 2025 to 2032, driven by the increasing prevalence of chronic diseases, rising smartphone usage, and expanding digital health infrastructure. Government-led healthcare digitization initiatives and a surge in demand for remote care solutions are accelerating DTx adoption across countries such as India, Japan, China, and South Korea. In addition, growing interest in preventive care and personalized digital solutions is enhancing patient engagement and improving treatment outcomes throughout the region.

Japan Digital Therapeutic (DTx) Market Insight

The Japan digital therapeutic (DTx) market captured the largest revenue share in Asia-Pacific in 2024, attributed to the country’s advanced healthcare infrastructure, aging population, and supportive regulatory environment. Japan has emerged as a leader in adopting clinically validated DTx solutions for managing hypertension, diabetes, and mental health. The integration of DTx platforms with electronic health records and national health insurance systems is further promoting usage. Moreover, partnerships between hospitals, insurers, and DTx developers are expanding accessibility and scaling adoption in both urban and rural areas.

India Digital Therapeutic (DTx) Market Insight

The India digital therapeutic (DTx) market is expected to grow at the highest CAGR during the forecast period, fueled by rapid urbanization, increasing digital literacy, and the rising burden of non-communicable diseases. India’s large population base, expanding smartphone penetration, and the government’s push for digital health through programs such as Ayushman Bharat Digital Mission are key enablers of DTx growth. Local startups are actively developing cost-effective, multilingual platforms for diabetes, cardiovascular, and behavioral health management, increasing DTx adoption across both metro cities and tier 2–3 regions.

China Digital Therapeutic (DTx) Market Insight

The China digital therapeutic (DTx) market is witnessing strong growth momentum, supported by government policies encouraging digital health innovation and a tech-savvy population. DTx platforms are being increasingly integrated into telemedicine and chronic disease management programs. With a significant share of chronic disease patients, China is embracing AI-enabled DTx for personalized treatment and real-time monitoring. Collaborations between tech companies and healthcare providers are driving platform scalability, especially in diabetes and mental health treatment pathways.

South Korea Digital Therapeutic (DTx) Market Insight

The South Korea digital therapeutic (DTx) market is rapidly advancing, underpinned by its robust ICT infrastructure, high digital literacy, and regulatory efforts to accelerate DTx commercialization. The Ministry of Food and Drug Safety (MFDS) has taken proactive steps to develop a regulatory framework for software-based therapies, enabling faster product approvals. South Korean consumers’ strong engagement with health tech and mobile wellness applications is promoting demand for DTx, especially in areas such as sleep disorders, mental health, and metabolic conditions.

Asia-Pacific Digital Therapeutic (DTx) Market Share

The Asia-Pacific digital therapeutic (DTx) industry is primarily led by well-established companies, including:

• CureApp, Inc. (Japan)
• Wellthy Therapeutics Pvt. Ltd. (India)
• JOGOHEALTH (India)
• Samsung Electronics Co., Ltd. (South Korea)
• Tunstall Australasia Pty Ltd (Australia)
• Biofourmis, Inc. (Singapore)
• Health2Sync Inc. (Taiwan)
• M3, Inc. (Japan)
• Smartfuture Pte. Ltd. (Singapore)
• AinOne Inc. (South Korea)
• Neurowyzr Pte. Ltd. (Singapore)
• Biorithm Pte. Ltd. (Singapore)
• Ubie, Inc. (Japan)
• RoundGlass LLC (India)
• Olive Union Inc. (Japan)
• Onsurity Technologies Pvt. Ltd. (India)
• Zoi Health Co., Ltd. (South Korea)
• MediHub Co., Ltd. (South Korea)
• CareVoice Digital Health Co. Ltd. (China)

What are the Recent Developments in Asia-Pacific Digital Therapeutic (DTx) Market?

• In May 2024, CureApp, Inc. (Japan), a pioneer in digital therapeutics, launched CureApp SC, an innovative smoking cessation DTx platform, in collaboration with the Japanese Ministry of Health. This clinically approved app-based therapy integrates behavioral guidance with AI-driven insights, enhancing patient outcomes through real-time feedback and personalized support. The launch reinforces Japan’s leadership in regulatory acceptance and clinical deployment of DTx solutions
• In March 2024, Wellthy Therapeutics (India) partnered with a major healthcare provider to deploy its chronic disease management platform across multiple cities in India. The multilingual, AI-powered DTx platform targets diabetes and cardiovascular diseases, enabling personalized care plans and remote monitoring. This strategic move expands digital health access to tier 2 and tier 3 regions, demonstrating the scalability of localized DTx solutions
• In February 2024, JOGO Health (India) introduced its neuroplasticity-based digital therapeutic in South Korea, aimed at treating stroke and incontinence through wearable biofeedback devices. The expansion into a new market highlight growing cross-border interest in non-invasive, software-driven therapies and showcases India’s innovation footprint in the global DTx landscape
• In January 2024, Samsung Medical Center (South Korea) launched a pilot project integrating digital therapeutics for sleep disorders and cognitive behavioral therapy (CBT) using a hospital-linked app platform. The project is part of a broader initiative to embed DTx into traditional care delivery, with real-time monitoring and clinical oversight, further advancing hybrid digital-health models in the country
• In December 2023, Tunstall Healthcare (Australia) collaborated with local public health authorities to implement a digital health intervention program for elderly patients with chronic conditions. The program combines wearable devices and DTx software to remotely track patient progress, prevent hospital readmissions, and promote independent living. This initiative reflects Australia's growing commitment to digital aging solutions and value-based care models

SKU-59880